Skip to main
GOSS
GOSS logo

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. benefits from strong key opinion leader (KOL) sentiment surrounding its PAH treatment candidate, PROSERA, with expectations of a treatment effect size between 25m to 30m in 6-minute walk distance (6MWD), suggesting significant therapeutic efficacy. The company has demonstrated positive results from its phase 2 TORREY trial, highlighting consistent benefits across multiple endpoints, including pulmonary vascular resistance (PVR) reduction and pro-BNP reduction, while maintaining a favorable safety profile and durability. Increased investor interest has been noted following the recent Cantor conference, further indicating optimistic perspectives on Gossamer Bio's future prospects within its clinical pipeline.

Bears say

Gossamer Bio's stock outlook is negative primarily due to a perceived mispricing of the market's expectations regarding the success of its lead asset, Seralutinib, despite the recent increase in stock value. This mispricing suggests that investor sentiment may not accurately reflect the true risks and potential setbacks related to the company’s pipeline. Furthermore, a lack of clarity on the probabilities of success for its various clinical-stage products could contribute to continued volatility and uncertainty in financial performance.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.